(This measure has not been amended since it was reported to the Senate on March 15, 2016. The summary of that version is repeated here.)
Adding Zika Virus to the FDA Priority Review Voucher Program Act
(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to add Zika virus disease to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)
The bill makes a technical correction to the tropical disease list to refer to filovirus disease, a condition caused by the family of viruses that includes the Ebola virus, instead of the family of viruses.